All Insights and Resources

GMP

The Cell & Gene Therapy Manufacturing Capacity Map

20 September 2023

The Cell & Gene Therapy Manufacturing Capacity Map

The only live, interactive manufacturing

Mustang Bio Announces Amendment and Closing of Manufacturing Partnership with uBriGene (Boston)

1 August 2023

Mustang Bio Announces Amendment and Closing of Manufacturing Partnership with uBriGene (Boston)

Mustang Bio has announced the

Delivering on the Promise of Cell and Gene Therapy Distributed and Point-of-Care Manufacturing

31 July 2023

Delivering on the Promise of Cell and Gene Therapy Distributed and Point-of-Care Manufacturing

At Advanced Therapies Week 2023,

Cell Sorter for Next Cell Therapy Products: The Sangamo & Sony Biotechnology Journey

20 July 2023

Cell Sorter for Next Cell Therapy Products: The Sangamo & Sony Biotechnology Journey

This Briefing from Advanced Therapies

POPULAR NEWS ITEMS

21 September 2023

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

20 September 2023

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

20 September 2023

The Cell & Gene Therapy Manufacturing Capacity Map

The Next Wave: Cell and Gene Therapy’s Commercial Shift

20 July 2023

The Next Wave: Cell and Gene Therapy’s Commercial Shift

This full session from Advanced

eXpDNA<sup>TM</sup> Plasmid Platform: Expediting Plasmid DNA Production and Supply

31 May 2023

eXpDNA^TM Plasmid Platform: Expediting Plasmid DNA Production and Supply

This Presentation from Advanced Therapies

CDMO, uBriGene, Expands to the US Market with Major Acquisition

19 May 2023

CDMO, uBriGene, Expands to the US Market with Major Acquisition

CDMO, uBriGene, Expands to the

Oxford Biomedica Launches Next Generation Lentiviral Vector System: TetraVecta™

18 May 2023

Oxford Biomedica Launches Next Generation Lentiviral Vector System: TetraVecta™

Oxford Biomedica launches TetraVecta™

RECOMENDED TOPICS

Automation & Digitisation

Characterisation

Skills, Talent & Development

POPULAR NEWS ITEMS

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

The Cell & Gene Therapy Manufacturing Capacity Map

logo_mobile_footer

Company

Resources

Network

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022